Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP1 in ASD Phenotype 1
NCT04644003Phase 1Completed
- Sponsor
- STALICLA
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ibudilast and bumetanide in Autism Spectrum Disorder (ASD) (3 arms), sponsored by STALICLA. Primary endpoint: Safety and Tolerability at 14 days. Started Dec 2020; status: completed.
02
Drugs
ibudilastbumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04644003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644003.